


believe the claims are in condition for allowance. The Examiner is invited to contact the undersigned if there are any remaining issues.

Respectfully submitted,



Dated: April 3, 2002

By: Richard J. Stein, Ph.D.
Registration No. 50,668
Heska Corporation
1613 Prospect Parkway
Fort Collins, Colorado 80525
Telephone: (970) 493-7272
Facsimile: (970) 491-9976



VERSION WITH MARKINGS SHOWING CHANGES

33. (Once amended) An isolated protein selected from the group consisting of:

(a) an isolated protein of at least about 20 amino acids in length, wherein said [protein is] 20 amino acids are encoded by a nucleic acid molecule[, wherein said nucleic acid molecule] that has an at least 60 contiguous nucleotide region identical in sequence to a 60 contiguous nucleotide region of a nucleic acid sequence selected from the group consisting of SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:104; and

(b) an isolated protein of at least about 20 amino acids in length, wherein said protein has an at least 20 contiguous amino acid region identical in sequence to a 20 contiguous amino acid region selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105,

wherein said isolated protein of (a) or (b) elicits an immune response against a canine IL-13 protein or has IL-13 activity.

34. (Once amended) The isolated protein of Claim 33, wherein said protein [is selected from the group consisting of:

(a) a protein having] has an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105[; and

(b) a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105].

35. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:92.

36. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:97.

37. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:100.

38. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:105.

39. (Reiterated) An isolated protein having an amino acid sequence that is at least about [70] 85 percent identical to an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105, wherein said isolated protein elicits an immune response against a canine IL-13 protein or has IL-13 activity.

40. (Once amended) A therapeutic composition comprising [a therapeutic compound selected from the group consisting of:

- (a)]the isolated protein of Claim 33[;
- (b) a mimotope of said protein of (a);
- (c) a multimeric form of said protein of (a);
- (d) an antibody that selectively binds to said protein of (a); and
- (e) an inhibitor of a immunoregulatory protein activity identified by its ability to inhibit the activity of said protein of (a)].

41. (Reiterated) The composition of Claim 40, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.

42. (Reiterated) A method to regulate an immune response in an animal comprising administering to the animal the therapeutic composition of Claim 40.

43. (Once amended) The method of Claim 42, wherein said animal is a canid [selected from the group consisting of canids].

44. (Reiterated) The method of Claim 42, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.

B